Jaysingh Brijkumar1, Johnathan A Edwards2,3,4, Brent A Johnson5, Claudia Ordonez2, Henry Sunpath1, Mitch Lee2, Mathew R Dudgeon2, Lydia Rautman2, Selvan Pillay1, Pravi Moodley6, Y V Sun2, José Castillo-Mancilla7, Jonathan Z Li8, Daniel R Kuritzkes8, Mohamed Y S Moosa1, Vincent Charles Marconi2,3,9. 1. University of KwaZulu Natal, Nelson R Mandela School of Medicine, Durban, South Africa. 2. Emory University Rollins School of Public Health, Atlanta, Georgia, USA. 3. Emory University School of Medicine, Atlanta, Georgia, USA. 4. University of Lincoln, School of Health and Social Care, Lincoln International Institute for Rural Health, Lincoln, UK. 5. University of Rochester, Rochester, New York, USA. 6. University of KwaZulu-Natal, School of Laboratory Medicine and Medical Sciences, National Health Laboratory Service, Durban, South Africa. 7. University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. 8. Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 9. Emory Vaccine Center, Atlanta, Georgia, USA.
Abstract
OBJECTIVES: Viral suppression (VS) is the hallmark of successful antiretroviral therapy (ART) programmes. We sought to compare clinic retention, virological outcomes, drug resistance and mortality between peri-urban and rural settings in South Africa after first-line ART. METHODS: Beginning in July 2014, 1000 (500 peri-urban and 500 rural) ART-naïve patients with HIV were enrolled and managed according to local standard of care. Clinic retention, virological suppression, virological failure (VF), genotypic drug resistance and mortality were assessed. The definition of VS was a viral load ≤1000 copies/ml. Time to event analyses were stratified by site, median age and gender. Kaplan-Meier curves were calculated and graphed with log-rank modelling to compare curves. RESULTS: Based on 2741 patient-years of follow-up, retention and mortality did not differ between sites. Among all 1000 participants, 47%, 84% and 91% had achieved VS by 6, 12 and 24 months, respectively, which was observed earlier in the peri-urban site. At both sites, men aged < 32 years had the highest proportion of VF (15.5%), while women aged > 32 years had the lowest, at 7.1% (p = 0.018). Among 55 genotypes, 42 (76.4%) had at one or more resistance mutations, which did not differ by site. K103N (59%) and M184V (52%) were the most common mutations, followed by V106M and K65R (31% each). Overall, death was infrequent (< 4%). CONCLUSIONS: No significant differences in treatment outcomes between peri-urban and rural clinics were observed. In both settings, young men were especially susceptible to clinic attrition and VF. More effective adherence support for this important demographic group is needed to achieve UNAIDS targets.
OBJECTIVES: Viral suppression (VS) is the hallmark of successful antiretroviral therapy (ART) programmes. We sought to compare clinic retention, virological outcomes, drug resistance and mortality between peri-urban and rural settings in South Africa after first-line ART. METHODS: Beginning in July 2014, 1000 (500 peri-urban and 500 rural) ART-naïve patients with HIV were enrolled and managed according to local standard of care. Clinic retention, virological suppression, virological failure (VF), genotypic drug resistance and mortality were assessed. The definition of VS was a viral load ≤1000 copies/ml. Time to event analyses were stratified by site, median age and gender. Kaplan-Meier curves were calculated and graphed with log-rank modelling to compare curves. RESULTS: Based on 2741 patient-years of follow-up, retention and mortality did not differ between sites. Among all 1000 participants, 47%, 84% and 91% had achieved VS by 6, 12 and 24 months, respectively, which was observed earlier in the peri-urban site. At both sites, men aged < 32 years had the highest proportion of VF (15.5%), while women aged > 32 years had the lowest, at 7.1% (p = 0.018). Among 55 genotypes, 42 (76.4%) had at one or more resistance mutations, which did not differ by site. K103N (59%) and M184V (52%) were the most common mutations, followed by V106M and K65R (31% each). Overall, death was infrequent (< 4%). CONCLUSIONS: No significant differences in treatment outcomes between peri-urban and rural clinics were observed. In both settings, young men were especially susceptible to clinic attrition and VF. More effective adherence support for this important demographic group is needed to achieve UNAIDS targets.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: T M Rossouw; M Nieuwoudt; J Manasa; G Malherbe; R J Lessells; S Pillay; S Danaviah; P Mahasha; G van Dyk; T de Oliveira Journal: HIV Med Date: 2016-06-28 Impact factor: 3.180
Authors: Diane E Bennett; Michael R Jordan; Silvia Bertagnolio; Steven Y Hong; Giovanni Ravasi; James H McMahon; Ahmed Saadani; Karen F Kelley Journal: Clin Infect Dis Date: 2012-05 Impact factor: 9.079
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Leslie Cottle; Xinyi C Zhang; Joseph Makhema; Lisa A Mills; Ravindre Panchia; Sharlaa Faesen; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David D Celentano; Max Essex; Sarah E Hudelson; Andrew D Redd; Thomas R Fleming Journal: N Engl J Med Date: 2016-07-18 Impact factor: 91.245
Authors: Olivier Koole; Sharon Tsui; Fred Wabwire-Mangen; Gideon Kwesigabo; Joris Menten; Modest Mulenga; Andrew Auld; Simon Agolory; Ya Diul Mukadi; Robert Colebunders; David R Bangsberg; Eric van Praag; Kwasi Torpey; Seymour Williams; Jonathan Kaplan; Aaron Zee; Julie Denison Journal: Trop Med Int Health Date: 2014-09-17 Impact factor: 2.622
Authors: J Brijkumar; B A Johnson; Y Zhao; J Edwards; P Moodley; K Pathan; S Pillay; K G Castro; H Sunpath; D R Kuritzkes; M Y S Moosa; V C Marconi Journal: BMC Infect Dis Date: 2020-11-11 Impact factor: 3.090